Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Painchek's interest expense for the
six
months ended in Dec. 2025 was A$ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Painchek's Operating Income for the
six
months ended in Dec. 2025 was A$ -4.83 Mil. Painchek's Interest Expense for the
six
months ended in Dec. 2025 was A$ 0.00 Mil.
Painchek has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Painchek (ASX:PCK) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Painchek's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as
Painchek had no long-term debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Painchek Ltd has no debt.
Painchek Interest Expense Historical Data
* Premium members only.
The historical data trend for Painchek's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Painchek (ASX:PCK) has a Interest Expense of A$0.00 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Painchek and its competitors.
Is Painchek's Interest Expense too high?
Painchek's current Interest Expense is A$0.00 Mil. Overall, Painchek has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Painchek's Interest Expense compare to VEEV and BTSG?
Painchek's Interest Expense of A$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Healthcare Providers & Services company?
A good Interest Expense depends on the Healthcare Providers & Services industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Painchek and its competitors. Painchek's current Interest Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.40, compared to a current price of A$0.11 — trading 73.8% below its estimated fair value. The current Interest Expense is A$0.00 Mil. Painchek's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Painchek (ASX:PCK), the current Interest Expense is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Painchek (ASX:PCK) Overvalued in 2026?
Based on GuruFocus' analysis, Painchek stock appears to be undervalued.
The current stock price of A$0.11 is trading 73.8% below its estimated GF Value™ of A$0.40.
GuruFocus considers Painchek to be Possible Value Trap.
Key valuation signals for ASX:PCK:
Interest Expense: A$0.00 Mil
GF Value™: A$0.40 vs. price of A$0.11 (73.8% below fair value)
No single metric tells the full story. See the ASX:PCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
52GF Score
Get the complete analysis for ASX:PCK
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PCK has been successfully added to your 
